MetaBioMed Signs KRW 2.9B Government 'Win-Win AX' Project Agreement
Predicted impact: Low· Actual: −6.1% vs sector, volume 1.4× normal (5 trading days)
KRW 2.9B government project agreement is about 3% of market value; small.
Metabiomed메타바이오메드
059210 · KOSDAQ · ₩059210 · 메타바이오메드
₩3,625▼ ₩10 (0.28%)End-of-day · Oct 29, 2026 · End-of-day prices.
Price · 1Y −35.95%
- Market cap
- ₩98B
- Enterprise value
- ₩129B
- P/E
- 5.8×
- P/B
- 0.8×
- Dividend yield
- 2.9%
- ROE
- 13.1%
- Net margin
- 16.8%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−42.9% from the high
₩3,265Today: ₩3,570 – ₩3,675₩6,350
Returns
- 1W−2.8%
- 1M−0.7%
- 3M−0.4%
- 6M−18.0%
- YTD−27.1%
- 1Y−36.0%
- Volume today
- 135,158
- 1.5× the 20-day average
- Traded today
- ₩491M
- Listed shares
- 27,171,445
- EPS (12 months)
- ₩625
- Earnings yield 17.3%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Normal- BuzzNormalBuzz 49 of 100 (50 is a normal day for this stock).
- MomentumFlat-2% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Metabiomed stock overview
Metabiomed (메타바이오메드, KRX: 059210) is listed on KOSDAQ, in the Biotech & Pharma sector. Meta Biomed is a Korean company that makes dental materials and equipment and synthetic bioabsorbable surgical sutures, which it supplies largely as semi-finished products to surgical-suture manufacturers. Its shares closed at ₩3,625 on Oct 29, 2026, down 0.28% on the day, giving it a market value of ₩98B.
Key facts
- Market cap
- ₩98B
- Sector
- Biotech & Pharma
- Latest price change
- −0.28%
- As of
- Oct 29, 2026
- Main business
- Meta Biomed is a Korean company that makes dental materials and equipment and synthetic bioabsorbable surgical sutures, which it supplies largely as semi-finished products to surgical-suture manufacturers.
Quick answers about Metabiomed
- What does Metabiomed do?
- Meta Biomed is a Korean company that makes dental materials and equipment and synthetic bioabsorbable surgical sutures, which it supplies largely as semi-finished products to surgical-suture manufacturers. Its dental segment provides root canal and restorative materials used in nerve treatment and tooth restoration, and it exports dental products to about 100 countries. The company also produces bone-repair materials, cosmetic and aesthetic threads and fillers, and sports-medicine devices, and it is developing soft-tissue anchors and laparoscopic surgical instruments.
- What is the market cap of Metabiomed?
- The market capitalisation of Metabiomed was ₩98B at the close on Oct 29, 2026.
- Who are the largest shareholders of Metabiomed?
- According to the latest official filings, the largest reported holders are Oh Seok-song (22.82%, as of Jun 12, 2026); Korea Securities Finance (4.33%, as of Oct 10, 2025); Oh Ji-su (1.72%, as of Jun 12, 2026).
- When is the next earnings report from Metabiomed?
- Korean companies rarely announce results dates in advance. Based on when Metabiomed filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
Meta Biomed is a Korean company that makes dental materials and equipment and synthetic bioabsorbable surgical sutures, which it supplies largely as semi-finished products to surgical-suture manufacturers. Its dental segment provides root canal and restorative materials used in nerve treatment and tooth restoration, and it exports dental products to about 100 countries. The company also produces bone-repair materials, cosmetic and aesthetic threads and fillers, and sports-medicine devices, and it is developing soft-tissue anchors and laparoscopic surgical instruments.
Written by AI from the company's latest annual report.
- Korean name
- 메타바이오메드
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 오석송
- Founded
- Jul 1999
- Listed
- Apr 2008
- Listed shares
- 27,171,445
- Fiscal year ends
- Month 12
- Website
- wwwlmeta-biomed.com
Similar companies
- Samsung Biologics207940 · ₩63T₩1,366,000−0.44%
- Celltrion068270 · ₩44T₩189,300−0.26%
- Alteogen196170 · ₩15T₩220,000−1.35%
- SK biopharmaceuticals326030 · ₩6.1T₩77,800+3.46%
- Yuhan000100 · ₩5.5T₩74,700−3.36%
- HLB028300 · ₩5.3T₩39,700−2.34%
- Hanmi Pharm128940 · ₩5T₩388,500+5.14%
- SAM Chun Dang Pharm000250 · ₩4.4T₩188,600−0.74%
Recent news
Recent filings
See all- Insider shareholding reportOct 2, 2026
- Investor relations (IR) eventSep 14, 2026
- Insider shareholding reportAug 25, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Insider shareholding reportJul 16, 2026
Titles in Korean until English translations are added.
Also known as: Metabiomed / 메타바이오메드 / 059210 / KRX:059210
Source: KRX statistical information